

Shannon W Finks

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8956607/publications.pdf>

Version: 2024-02-01

29
papers

398
citations

687220

13
h-index

752573

20
g-index

30
all docs

30
docs citations

30
times ranked

687
citing authors

#	ARTICLE	IF	CITATIONS
1	Assessing the Impact of Comprehensive Medication Management on Achievement of the Quadruple Aim. American Journal of Medicine, 2021, 134, 456-461.	0.6	28
2	Medication Optimization: Integration of Comprehensive Medication Management into Practice.. American Health and Drug Benefits, 2021, 14, 111-114.	0.5	0
3	The Fall Risk with Alpha blockers Given Initial dose or Elderly status (FRAGILE) Study. Annals of Pharmacotherapy, 2020, 54, 226-231.	0.9	1
4	Dual Antiplatelet Therapy for Long-term Secondary Prevention of Atherosclerotic Cardiovascular Events. Clinical Therapeutics, 2020, 42, 2084-2097.	1.1	4
5	Treating Hypertension in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2020, 382, 353-363.	13.9	23
6	A New Option for Reversing the Anticoagulant Effect of Factor Xa Inhibitors: Andexanet Alfa (ANDEXXA). American Journal of Medicine, 2019, 132, 38-41.	0.6	25
7	Contemporary Management of Direct Oral Anticoagulants During Cardioversion and Ablation for Nonvalvular Atrial Fibrillation. Pharmacotherapy, 2019, 39, 94-108.	1.2	2
8	An Underappreciated and Prolonged Drug Interaction Leads to Ineffective Anticoagulation. Southern Medical Journal, 2019, 112, 125-129.	0.3	4
9	Periprocedural Management of Direct Oral Anticoagulants Surrounding Cardioversion and Invasive Electrophysiological Procedures. Cardiology in Review, 2018, 26, 245-254.	0.6	2
10	Idarucizumab (Praxbind): The First Reversal Agent for a Direct Oral Anticoagulant. American Journal of Medicine, 2017, 130, e195-e197.	0.6	14
11	Edoxaban: How Does the Newest Agent Fit into the DOAC Landscape?. American Journal of Medicine, 2017, 130, 900-906.	0.6	6
12	Evaluation of bleeding in patients receiving direct oral anticoagulants. Vascular Health and Risk Management, 2017, Volume 13, 325-342.	1.0	78
13	Duration of triple antithrombotic therapy and outcomes among patients undergoing percutaneous coronary intervention. Cardiovascular Diagnosis and Therapy, 2017, 7, S66-S68.	0.7	1
14	Reversal Agents for Direct Oral Anticoagulants. Cardiology in Review, 2016, 24, 310-315.	0.6	13
15	Management of Venous Thromboembolism. Annals of Pharmacotherapy, 2016, 50, 486-501.	0.9	21
16	Heparin Versus Bivalirudin Monotherapy in the Setting of Primary Percutaneous Coronary Intervention for Patients With ST-Segment Elevation Myocardial Infarction. Annals of Pharmacotherapy, 2016, 50, 141-151.	0.9	2
17	Sorting It Out: What JNC 8 Is and What It Is Not. Journal of Managed Care & Specialty Pharmacy, 2015, 21, 110-112.	0.5	2
18	Key Articles and Guidelines in the Management of Hypertension. Journal of Pharmacy Practice, 2015, 28, 146-161.	0.5	3

#	ARTICLE	IF	CITATIONS
19	Clinical Efficacy and Safety of Cilostazol: A Critical Review of the Literature. <i>Drugs</i> , 2015, 75, 377-395.	4.9	52
20	Avoiding patient morbidity. <i>Nurse Practitioner</i> , 2014, 39, 45-51.	0.2	5
21	Life-Threatening ACE Inhibitor-Induced Angioedema After Eleven Years on Lisinopril. <i>Journal of Pharmacy Practice</i> , 2013, 26, 382-388.	0.5	16
22	Use of Cilostazol in Percutaneous Coronary Interventions. <i>Annals of Pharmacotherapy</i> , 2012, 46, 839-850.	0.9	14
23	Annual Influenza Vaccination. <i>Southern Medical Journal</i> , 2012, 105, 379-386.	0.3	6
24	Assessment of sotalol prescribing in a community hospital: opportunities for clinical pharmacist involvement. <i>International Journal of Pharmacy Practice</i> , 2011, 19, 281-286.	0.3	2
25	Activities of Memphis-area hospitals to meet National Patient Safety Goals for warfarin therapy. <i>American Journal of Health-System Pharmacy</i> , 2009, 66, 2179-2188.	0.5	5
26	Bivalirudin for Patients with Heparin-Induced Thrombocytopenia Undergoing Cardiovascular Surgery. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1304-1309.	0.9	20
27	Re-examining the Cardiovascular Therapeutic Benefits of Aspirin. <i>Southern Medical Journal</i> , 2008, 101, 679-680.	0.3	0
28	Hydralazine-induced Lupus: Maintaining Vigilance with Increased Use in Patients with Heart Failure. <i>Southern Medical Journal</i> , 2006, 99, 18-22.	0.3	34
29	Bivalirudin Use in Carotid Endarterectomy in a Patient with Heparin-Induced Thrombocytopenia. <i>Annals of Pharmacotherapy</i> , 2006, 40, 340-343.	0.9	14